<DOC>
	<DOCNO>NCT00790335</DOCNO>
	<brief_summary>The purpose study determine use adjunctive Pharmacomechanical Catheter Directed Thrombolysis , include intrathrombus administration rt-PA -- Activase ( Alteplase ) , prevent post-thrombotic syndrome ( PTS ) patient symptomatic proximal deep vein thrombosis ( DVT ) compare optimal standard DVT therapy alone .</brief_summary>
	<brief_title>Acute Venous Thrombosis : Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis</brief_title>
	<detailed_description>Activase , study drug , fibrinolytic drug indicate use acute myocardial infarction , acute ischemic stroke , acute massive pulmonary embolism adult . Previous study establish ability rt-PA lyse venous thrombus patient deep vein thrombosis ( DVT ) , suggest successful rt-PA mediate thrombolysis prevent post-thrombotic syndrome ( PTS ) , morbid , late complication DVT occur nearly 50 % patient . rt-PA deliver directly venous thrombus use catheter/device embed within thrombus physician imaging guidance . This method rt-PA delivery , pharmacomechanical catheter-directed intrathrombus thrombolysis ( PCDT ) , think safer , effective , efficient previous method . The question whether PCDT use rt-PA improves long-term DVT patient outcomes acceptable risk cost yet address . The rationale perform ATTRACT Trial base upon : - major burden PTS DVT patient U.S. healthcare system - association rapid clot lysis prevention PTS - proven ability rt-PA dissolve venous thrombus proximal DVT - recent advance CDT method may lower bleed risk - major clinical controversy whether CDT routinely use first-line DVT therapy</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Postthrombotic Syndrome</mesh_term>
	<mesh_term>Postphlebitic Syndrome</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Symptomatic proximal DVT involve iliac , common femoral , and/or femoral vein . Age le 16 year great 75 year . Symptom duration &gt; 14 day DVT episode index leg ( i.e. , nonacute DVT ) . In index leg : establish PTS , previous symptomatic DVT within last 2 year . In contralateral ( nonindex ) leg : symptomatic acute DVT ) involve iliac and/or common femoral vein ; b ) thrombolysis plan part initial therapy . Limbthreatening circulatory compromise . PE hemodynamic compromise ( i.e. , hypotension ) . Inability tolerate PCDT procedure due severe dyspnea acute systemic illness . Allergy , hypersensitivity , thrombocytopenia heparin , rtPA , iodinate contrast , except mildmoderate contrast allergy steroid premedication use . Hemoglobin &lt; 9.0 mg/dl , INR &gt; 1.6 warfarin start , platelet &lt; 100,000/ml . Moderate renal impairment diabetic patient ( estimate GFR &lt; 60 ml/min ) severe renal impairment nondiabetic patient ( estimate GFR &lt; 30 ml/min ) . Active bleeding , recent ( &lt; 3 mo ) GI bleeding , severe liver dysfunction , bleed diathesis . Recent ( &lt; 3 mo ) internal eye surgery hemorrhagic retinopathy ; recent ( &lt; 10 day ) major surgery , cataract surgery , trauma , CPR , obstetrical delivery , invasive procedure . History stroke intracranial/intraspinal bleed , tumor , vascular malformation , aneurysm . Active cancer ( metastatic , progressive , treat within last 6 month ) . Exception : patient nonmelanoma primary skin cancer eligible participate study . Severe hypertension repeat reading ( systolic &gt; 180 mmHg diastolic &gt; 105 mmHg ) . Pregnant ( positive pregnancy test , woman childbearing potential must test ) . Recently ( &lt; 1 mo ) thrombolysis participate another investigational drug study . Use thienopyridine antiplatelet drug ( except clopidogrel ) last 5 day . Life expectancy &lt; 2 year chronic nonambulatory status . Inability provide inform consent comply study assessment ( e.g . due cognitive impairment geographic distance ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>deep vein thrombosis</keyword>
	<keyword>deep venous thrombosis</keyword>
	<keyword>post thrombotic syndrome</keyword>
	<keyword>blood clot</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>tissue plasminogen activator</keyword>
	<keyword>rt-PA</keyword>
	<keyword>Activase</keyword>
	<keyword>mechanical thrombectomy</keyword>
	<keyword>pharmacomechanical</keyword>
	<keyword>ATTRACT</keyword>
</DOC>